Preliminary programme

Extended info:

Sun 19 Oct 2025

17:00 - 20:00

Poster mounting REG02

Poster Halls

Registration desk open REG01

Registration desk

Mon 20 Oct 2025

09:00 - 18:00

Registration desk open REG03

Registration desk

10:00 - 11:00

PLE

Plenary opening and keynotes PLE01

Auditorium 1 - Plenary Hall

Chairs

Colin RUSSELL

ESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands

Ab OSTERHAUS

ESWI Board Member, TiHO, Germany

Stefania MAGGI

ESWI Board Member, National Research Council of Italy, Italy

Marco GOEIJENBIER

ESWI Board Member, Spaarne Gasthuis, Netherlands

Opening word by the conference chairs: The 10th ESWI Influenza Conference

Colin RUSSELLESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands
Opening address

Monica GARCIA GÓMEZSpanish Ministry of Health, Spain
Long Covid

Peter OPENSHAWESWI Board Member, Imperial College, UK

11:00 - 11:30

Coffee Break COF01

Exhibition hall

Poster mounting REG04

Poster Halls

11:30 - 13:00

SCS

Innate and adaptive immunity SCS01

Auditorium 1 - Plenary Hall

Chairs

Guus RIMMELZWAAN

University of Veterinary Medicine, Hannover, Germany

Kevin SELVA

Doherty Institute, University of Melbourne, Australia

Increasing SARS-CoV-2 IgG4 following repeated mRNA boosters negatively impact antibody functions across Omicron variants and sarbecoviruses

Kevin SELVADoherty Institute, University of Melbourne, Australia
Impact of Aging on CD8+ T Cell Immunity to Circulating and Pandemic Viruses

Carolien VAN DE SANDTESWI Associate Member, The University of Melbourne at the Doherty Institute, Australia
Detection of pre-existing humoral immunity against influenza virus H5N1 clade 2.3.4.4b in unexposed individuals

Christoph KREERUniversity of Cologne, Germany
SYSTEMIC AND MUCOSAL ANTIBODY SIGNATURES OF PROTECTION AGAINST SARS-COV-2 TRANSMISSION

Amaya ROJO FERNANDEZIcahn School of Medicine at Mount Sinai, United States
Obesity modulates tracheal and cardiac responses to influenza A virus infection

Betina Lyngfeldt HENRIKSENTechnical University of Denmark, Denmark
Prior influenza vaccination shapes subsequent vaccine responses in a randomized placebo-controlled trial

Marcos VIEIRAUniversity of Chicago, United States

SCS

Pandemic Preparedness SCS02

Auditorium 2 - Breakout

Chairs

Ab OSTERHAUS

ESWI Board Member, TiHO, Germany

Nico Joel HALWE

Ludwig Boltzmann Gesellschaft, Austria

Observed Immunogenicity After Two Doses of an MF59-Adjuvanted Cell Culture–Derived H5N8 Influenza Vaccine (aH5N8c) in Healthy Subjects Aged ≥18 Years

Janine OBERIJECSL R&D - Vaccines Innovation Unit, Netherlands
Immunogenicity of Homologous or Heterologous Booster Vaccinations with MF59-Adjuvanted, Cell Culture–Derived H5N8 or H5N6 Influenza Vaccines in Healthy Subjects Aged ≥18 Years

Eve VERSAGECSL Seqirus, United States
When can sequence data confirm transmission links in respiratory virus outbreaks?

Simon DE JONGAmsterdam University Medical Centers, Netherlands
Broad-Spectrum Baseline Immunity Against Highly Pathogenic Avian Influenza A(H5N1) Clade 2.3.4.4b Viruses in Dutch Healthcare Workers: Insights into Both Humoral and Cellular Immune Responses

Willemijn RIJNINKErasmus MC, Netherlands
Evaluating Cross-Protective Antibody Responses to Influenza A(H5N8) Vaccine in High-Risk Groups

Oona LIEDESFinnish Institute for Health and Welfare, Finland
OVX836, a Nucleoprotein based vaccine under clinical development, offers protection against Highly Pathogenic Avian Influenza viruses (H5N1 and H7N9) in mouse and ferret models

Florence NICOLASOsivax, France

SPI

ESWI invites coalition partners: Life Course Immunisation: A Seamless Approach to Protection Across All Ages SPI01

Auditorium 3 - Breakout

Chairs

Stefania MAGGI

ESWI Board Member, National Research Council of Italy, Italy

Catherine WEIL OLIVIER

independent expert, Trustee of CLCI, France

Understanding life course immunisation

Stefania MAGGIESWI Board Member, National Research Council of Italy, Italy

Catherine WEIL OLIVIERindependent expert, Trustee of CLCI, France
Age-specific immunisation needs and challenges

Paula TÄHTINENESWI Board Member, Turku University Hospital and University of Turku, Finland

Nicola VERONESEUnicamillus University, Italy
Burden of disease

Catherine MOOREPublic Health Wales, UK
Nurses and Pharmacists as Immunisation Champions

Ber OOMENESNO, Netherlands

13:00 - 14:30

Lunch LUN01

Exhibition hall

Poster mounting REG05

Poster Halls

13:15 - 14:15

SAT

Satellite Symposium organised by AstraZeneca: Unfolding the story of the immune response to intranasal live attenuated influenza vaccines SAT01

Auditorium 2 - Breakout

14:30 - 16:00

SCS

Future vaccination strategies - PART 1 SCS03

Auditorium 1 - Plenary Hall

Chairs

Florian KRAMMER

ESWI Board Member, Medical University of Vienna, Austria

Yona TUGG

McMaster University, Canada

A Dendritic Cell-targeting Approach to Deliver a Universal Influenza Vaccine Candidate to the Respiratory Mucosa

Daryl LEENational University of Singapore, Singapore
Development of a next-generation COVID-19 intranasal vaccine based on a multivalent NDV-HXP-S formulation.

Marta BOZA CUENCAIcahn School of Medicine at Mount Sinai, United States
Superior protection and prevention of transmission upon influenza infection by adjuvanted mucosal vaccination in the guinea pig influenza model.

Michael SCHOTSAERTIcahn School of Medicine at Mount Sinai, United States
Broad betacoronavirus immunity and SARS-CoV-2 protection induced by divergent spike-based nucleoside-modified vaccines

Anass ABBADIcahn Medical School at Mount Sinai, United States
The Additive Effect of Neuraminidase Inclusion in Influenza Vaccine Formulations using a Self-Amplifying RNA Platform

Giuseppe PALLADINOCSL, United States
Evaluation of a broadly protective influenza B virus vaccine based on mosaic hemagglutinin platforms in mice.

Irene GONZÁLEZ-DOMÍNGUEZIcahn School of Medicine at Mount Sinai, United States

SCS

Virus and host factors in pathogenesis - PART 1 SCS04

Auditorium 2 - Breakout

Chairs

Debby VAN RIEL

ESWI Associate Member, Erasmus MC, Netherlands

Anders MADSEN

Haukeland University Hospital, Norway

Avian influenza viruses re-shape the hormonal landscape by inducing pulmonary CYP19A1 expression in golden hamsters

Sebastian BECKLeibniz Institute of Virology, Germany
Obesity increases the risk for severe COVID 19 – An obese hamster model to study sex-specific differences in the underlying pathophysiology

Zoé SCHMALLeibniz Institute of Virology, Germany
Functional Balance of HA and NA in Emerging Porcine Influenza A Viruses: Sialoreceptor Dynamics at the Mucosal Interface

Mengying LIUUtrecht University, Netherlands
Cell Tropism, Replication Dynamics, and effect on neural network activity to Seasonal and Pandemic Influenza A Virus Infection in a hiPSC-Derived Neural Co-Culture Model

Feline BENAVIDESErasmus MC, Netherlands
Single-cell profiling of inflammatory lung injury in clade 2.3.4.4b H5N1 influenza infected mice

Ying LIUThe University of Hong Kong, Hong Kong SAR China
A history of obesity increases influenza severity via innate immune training in a canonical NLRP3-dependent manner

Katina HULMEAmsterdam UMC, Netherlands

SPI

Burden of disease in acute respiratory virus infections SPI02

Auditorium 3 - Breakout

Chairs

Paula TÄHTINEN

ESWI Board Member, Turku University Hospital and University of Turku, Finland

Stefania MAGGI

ESWI Board Member, National Research Council of Italy, Italy

Risk factors associated with severe health outcomes among older adults hospitalized with respiratory syncytial virus (RSV): understanding the pre-vaccine era landscape

Vajini ATUKORALEUniversity of Toronto, Canada

16:00 - 16:30

Coffee Break COF02

Exhibition hall

Poster mounting REG06

Poster Halls

16:30 - 17:30

SAT

Satellite Symposium SAT02

Auditorium 1 - Plenary Hall

SAT

Satellite Symposium organised by Pfizer: RSV Vaccination in Adults: Integrating Current Clinical Trial Data and Real-World Insights SAT03

Auditorium 2 - Breakout

SAT

Satellite Symposium organised by the ESWI IDC and supported by IFPMA: The Bidirectional Relationship Between Metabolic and Cardiovascular Conditions and Respiratory Viral Infections (SARS-CoV-2, Influenza, RSV) SAT11

Auditorium 3 - Breakout

Chair

Marco GOEIJENBIER

ESWI Board Member, Spaarne Gasthuis, Netherlands

Introduction to the topic: the evolving link between NCDs and respiratory infections, with a historical look at flu and diabetes and the IDC

Marco GOEIJENBIERESWI Board Member, Spaarne Gasthuis, Netherlands
The Impact of Glycemic Variability on Influenza Outcomes in Intensive Care Patients

Ramon FLUITSpaarne Ziekenhuis: Spaarne Gasthuis, Netherlands
How do her extensive line of research complement Ramon’s data? What new insights are emerging, and what does she want to study next?

Kirsty SHORTESWI Associate Member, University of Queensland, Australia
Could obesity be the key link connecting NCDs and increased susceptibility to respiratory infections?

Stacey SCHULTZ-CHERRYSt Jude Children's Research Hospital, United States
Broader clinical implications: Are these insights already impacting practice or guidelines?

Oana SANDULESCUCarol Davila University of Medicine and Pharmacy, National Institute for Infectious Diseases Prof Dr Matei Bals, Romania
A wrap-up with implications for vaccination: all data points to support, but what are the current boundaries or uncertainties? Why is VCR decreasing?

Eric C.M. VAN GORPErasmus MC, Netherlands

17:30 - 19:00

Welcome Refreshments and networking DIN01

Exhibition hall

19:00 - 20:00

ECAS

Early Career Scientists workshop - Communicating science - invitation only ECAS01

External

Tue 21 Oct 2025

08:15 - 09:15

SAT

Satellite Symposium: : A Shot in the Arm: Leveraging Combination Vaccines for Global Health Impact (a PeerVoice symposium supported by an educational grant from Moderna) SAT05

Auditorium 2 - Breakout

09:30 - 10:30

PLE

Science, Public Health, and Funding in a changing world PLE02

Auditorium 1 - Plenary Hall

Chair

Ab OSTERHAUS

ESWI Board Member, TiHO, Germany

10:30 - 11:00

Coffee Break COF03

Exhibition hall

11:00 - 12:30

SCS

Epidemiology and surveillance SCS05

Auditorium 1 - Plenary Hall

Chairs

Monika REDLBERGER-FRITZ

Medical University Vienna, Austria

Marco DEL RICCIO

University of Florence, Italy

Age at First Influenza A Virus Infection in Children and Impact of Influenza Vaccination

Kayla HANSONUniversity of Michigan School of Public Health, United States
Association of influenza viral genetic information with disease severity markers in hospitalized patients

Aung Pone MYINTUCBL1, France
Population-based Surveillance shows Burden of Hospitalisations and Severe Disease due to hMPV, RSV, and Influenza in Older Adults

To be confirmed
Impact of COVID-19 non-pharmaceutical interventions on antibody waning and the resurgence of human respiratory syncytial virus, seasonal coronavirus and influenza virus in a prospective cohort in The Netherlands

Channah GAASBEEKRIVM, Netherlands
Epidemiology of hospitalizations in older adults with lab-confirmed hMPV infection: A 14-year time series

To be confirmed
Epidemiology of human coronaviruses and impact of SARS-CoV-2 vaccination in paediatric patients in Hong Kong

Zirui GUOThe University of Hong Kong, Hong Kong SAR China

SCS

Molecular virology: Virus evolution, strain selection, structure and replication SCS16

Auditorium 2 - Breakout

Chairs

Corine GEURTS VAN KESSEL

Erasmus MC, Netherlands

Jurre SIEGERS

Institut Pasteur du Cambodge, Cambodia

Antigenic drift in the receptor binding site of H1N1 balances antibody evasion and receptor binding

Jenna GUTHMILLERUniversity of Colorado Anschutz Medical Campus, United States
HA Mutations Driving Immune Escape in Avian Influenza Virus Do Not Enhance Human Receptor Binding

To be confirmed
Multivalent Colocalization of Influenza Polymerase and Nucleoprotein by ANP32A Reveals the Molecular Basis of Human Adaptation

To be confirmed
Molecular basis of 60 years of antigenic evolution of human influenza A(H3N2) virus neuraminidase

Ron FOUCHIERErasmus MC, Netherlands
Little evidence for additional mammalian adaptation in bovine-derived H5N1 viruses during replication or transmission in ferrets

To be confirmed

SPI

How scientific evidence guides policy: lessons learned SPI03

Auditorium 3 - Breakout

Chairs

Joseph BRESEE

Task Force for Global Health, United States

Ann MOEN

Task Force for Global Health, United States

NITAGs and Evidence for Influenza Vaccine Recommendations in Middle Income Countries

Lisandro TORRETask Force for Global Health, United States

12:30 - 14:00

Lunch LUN02

Exhibition hall

12:45 - 13:45

SAT

Satellite Symposium organised by Sanofi: Good, better and best: Shoot the flu with your best shot! SAT06

Auditorium 2 - Breakout

14:00 - 15:30

SCS

Pharmaceutical and non pharmaceutical intervention SCS07

Auditorium 1 - Plenary Hall

Chairs

Benjamin COWLING

The University of Hong Kong, Hong Kong SAR China

Nisreen OKBA

Icahn School of Medicine at Mount Sinai, United States

Estimated Relative Effectiveness and Public Health Impact of Cell-Based Versus Egg Based Influenza Vaccines During the 2023–2024 Season in the United States

Alicia STEINCSL Seqirus, Australia
Effectiveness of 2024/25 COVID-19 vaccines against symptomatic SARS-CoV-2 infection in the target group for vaccination, European VEBIS primary care multicentre study, autumn/winter 2024/25

To be confirmed
Differential protection of prior infection and repeated vaccination against SARS-CoV-2 infection in Omicron BA.2 to JN.1 predominance: a prospective cohort study

Nicole Ngai Yung TSANGThe University of Hong Kong, Hong Kong SAR China
Vaccine effectiveness against medically attended influenza at primary care level in the paediatric population, 2024/25 season, Europe

Héloïse LUCACCIONIEpiconcept, France
IMMUNOGENICITY AND SAFETY OF HIGH DOSE FORMULATIONS OF MF59-ADJUVANTED CELL-DERIVED INFLUENZA VACCINE IN ADULTS AGED 50 YEARS AND OLDER: TWO PHASE 2 RANDOMISED CONTROLLED TRIALS

Frank ALBANOCSL Seqirus, Australia
High-dose recombinant influenza vaccines induce greater A(H3N2)-reactive antibodies and overcome attenuation associated with repeated vaccination compared to standard-dose egg- or cell-based vaccines: results from a RCT in healthy younger adults

To be confirmed

SCS

Mathematical modelling and projections, including limitations SCS08

Auditorium 2 - Breakout

Chairs

Colin RUSSELL

ESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands

Weijia XIONG

The University of Hong Kong, Hong Kong SAR China

A Framework for Measuring Population Immunity Against Influenza Using Individual Antibody Titers

Weijia XIONGThe University of Hong Kong, Hong Kong SAR China
serojump: A Bayesian tool for inferring infection timing and antibody kinetics from longitudinal serological data

David HODGSONLondon School of Hygiene and Tropical Medicine, UK
Integrating Serology and PCR to Infer RSV Infection Dynamics and Correlates of Protection in a Community Cohort in The Gambia

Thushan DE SILVAUniversity of Sheffield, UK
Joint reconstruction of influenza A(H1N1) and A(H3N2) antibody dynamics to estimate the risk of influenza virus infection

Tim TSANGThe University of Hong Kong, Hong Kong SAR China
Investigating the predictive power of machine learning algorithms for antigenic novelty of influenza H3 viruses

Lucy GREENWOODUniversity of Oxford, UK
Comparative Pre-symptomatic Transmission Potential of Influenza A and SARS-CoV-2 in Households

Chengyao ZHANGUniversity of Hong Kong, Hong Kong SAR China

SPI

Implementation of adult and risk groups national immunisation programmes SPI04

Auditorium 3 - Breakout

Chairs

Ted VAN ESSEN

ESWI Board Member, Netherlands

George KASSIANOS

ESWI Board Member, G Kassianos

Effectiveness of Maternal Influenza Vaccination in Preventing Influenza Infection in Infants Aged ≤ 6 Months in Korea

Yoonsun YOONKorea University Guro Hospital, South Korea
Preliminary observation of impact of Maternal RSV Vaccination on Infant Hospitalizations in Mendoza, Argentina: A Comparative Study of the 2023 and 2024 Seasons

Juan Manuel FERNANDEZ MUÑOZMinistry of Health of Mendoza, Argentina
Implementing Adult Vaccination in Europe: Lessons from the AIB Meeting

Marco DEL RICCIOUniversity of Florence, Italy
SPI Roundtables in Europe Lessons from Czech Republic and Austria

Roman PRYMULAESWI Board Member, Postgraduate Medical School, Czechia

Monika REDLBERGER-FRITZMedical University Vienna, Austria

15:30 - 16:00

Coffee Break COF04

Exhibition hall

16:00 - 17:00

SAT

Satellite Symposium organised by CSL Seqirus: Addressing the evolving influenza landscape: a public health imperative SAT07

Auditorium 2 - Breakout

17:00 - 18:30

POS

Poster presentations "Test Tubes" and refreshments POS01

Poster Halls

18:30 - 19:30

ECAS

Early Career Scientists event and panel discussion "Life after Phd" - invitation only - with the support of AstraZeneca, CSL Seqirus and Sanofi ECAS02

External

Wed 22 Oct 2025

08:15 - 09:15

SAT

Satellite Symposium organised by the Global Influenza Initiative: Preventing influenza to safeguard aging populations SAT08

Auditorium 2 - Breakout

Chair

Litjen (L.J) TAN

Global Influenza Initiative; Immunize.org, United States

Welcome and setting the scene

Litjen (L.J) TANGlobal Influenza Initiative; Immunize.org, United States
Navigating the 2024-2025 flu season: insights on severity, vaccine uptake and impact

Litjen (L.J) TANGlobal Influenza Initiative; Immunize.org, United States

Mine DURUSU TANRIOVERHacettepe University, Türkiye
Understanding what shapes influenza vaccine decisions by HCP's and patients

Salah AL AWAIDIMinistry of Health (Oman), Oman

Litjen (L.J) TANGlobal Influenza Initiative; Immunize.org, United States

Mine DURUSU TANRIOVERHacettepe University, Türkiye

George KASSIANOSESWI Board Member, G Kassianos, UK
Strengthening partnerships for lifelong wellness

Salah AL AWAIDIMinistry of Health (Oman), Oman

Litjen (L.J) TANGlobal Influenza Initiative; Immunize.org, United States

Mine DURUSU TANRIOVERHacettepe University, Türkiye

George KASSIANOSESWI Board Member, G Kassianos, UK
Summary and close

Litjen (L.J) TANGlobal Influenza Initiative; Immunize.org, United States

09:30 - 10:30

PLE

Keynotes PLE03

Auditorium 1 - Plenary Hall

10:30 - 11:00

Coffee Break COF05

Exhibition hall

11:00 - 12:30

SCS

Future vaccination strategies - PART 2 SCS09

Auditorium 1 - Plenary Hall

Chairs

Florian KRAMMER

ESWI Board Member, Medical University of Vienna, Austria

Marios KOUTSAKOS

University of Melbourne, Australia

A Novel Antigenically Central HA mRNA Vaccine Confers Humoral and Cellular Immune Responses and Protects Ferrets Against Challenge With a Heterologous A(H5) Clade 2.3.4.4b Highly Pathogenic Avian Influenza Virus

Willemijn RIJNINKErasmus MC, Netherlands
Breast milk-derived secretory IgA provides broad protection against influenza A virus

Yona TUGGMcMaster University, Canada
Hemagglutination inhibition antibody titer as correlate of protection against influenza virus infection: a systematic review and meta-analysis

Nancy H. L. LEUNGThe University of Hong Kong, Hong Kong SAR China
Pooled Long-Term Safety Analysis of a Phase 1/2/3 Randomized, Observer-Blind, Controlled Study of the Self-Amplifying mRNA COVID-19 Vaccine ARCT-154 in Adults

Josephine VAN BOXMEERCSL Seqirus, Netherlands
Decades of Evidence Revisited: A Systematic Review on Anti-Neuraminidase Antibody Responses and Influenza-related Outcomes

To be confirmed
Immunogenicity and Reactogenicity of an mRNA-Based Seasonal Influenza and SARS-CoV-2 Multicomponent Vaccine (mRNA-1083) in Adults ≥65 Years With Comorbidities

Lusine KOSTANYANModerna, Inc., United States

SCS

Human challenge studies SCS11

Auditorium 2 - Breakout

Chair

Ab OSTERHAUS

ESWI Board Member, TiHO, Germany

Disease characteristics and immunological profiles obtained from a newly developed hMPV human challenge model

Brandon LONDThVIVO, UK
Evolution of Human Metapneumovirus (HMPV) over the last 20 years and superior isolation of HMPV from clinical samples in organoid-derived bronchial cell cultures to isolation in monolayer cell line cultures

Bernadette VAN DEN HOOGENErasmusMC, Netherlands
A Study of the Efficacy, Safety and Immunogenicity of mRNA vaccines in an Influenza B Challenge Model in Healthy Adults

Anita GEEVARUGHESEPfizer, United States
Development of a Severe Acute Respiratory Syndrome – Coronavirus 2 (SARS-CoV-2) Omicron BA5 human challenge model (HCM) for the assessment of new vaccine and anti-viral therapies in seropositive subjects

Andrew CATCHPOLEhVIVO, UK
Establishing a Controlled Human Infection Model with a contemporary Respiratory Syncytial Virus B challenge agent in healthy volunteers

To be confirmed

SCS

Clinical Manifestations, burden of disease and management SCS10

Auditorium 3 - Breakout

Chairs

Marco GOEIJENBIER

ESWI Board Member, Spaarne Gasthuis, Netherlands

Valentino D'ONOFRIO

Ghent University, Belgium

Burden of Influenza Hospitalisation (Including With Recent COVID-19) Among Individuals With Immunocompromising Conditions and Other Comorbidities: An Exploratory Analysis Using the INFORM Study Cohort

Wilhelmine MEERAUSAstraZeneca, UK
Is clinical outcome pathogen related? Characteristics and Outcomes of ICU Patients with Severe Acute Respiratory Infections: Focusing on Respiratory Syncytial Virus, Human Metapneumovirus, Influenza virus, and Parainfluenza virus

Sjoerd VAN DER BIESpaarne Gasthuis, Netherlands
Hospital Burden of Respiratory Syncytial Virus (RSV) in Adults Aged 18 to 60 Years in France: A Nationwide Analysis (2018–2023)

Clarisse DEMONTModerna, France
Clinical outcomes among older adults hospitalized with respiratory syncytial virus and influenza infection – a retrospective study from Israel

Michal MANDELBOIMIsrael Ministry of Health, Israel
The Effect of Revaccination and Reinfection on Symptom Severity and Prevalence in a Post Covid-19 Condition Cohort

Emma VAN DER SPEKNational Institute for Public Health and the Environment (RIVM), Netherlands
RSV in Patients with Hematological Malignancies: A Multi-centre Retrospective Cohort Study

To be confirmed

12:30 - 14:00

Lunch LUN03

Exhibition hall

12:45 - 13:45

SAT

Satellite Symposium SAT09

Auditorium 2 - Breakout

14:00 - 15:30

SCS

Antiviral and immune therapy SCS12

Auditorium 1 - Plenary Hall

Chairs

Adolfo GARCÍA-SASTRE

Icahn School of Medicine at Mount Sinai, United States

Josefine SCHROEDER

Jena University Hospital, Germany

Effectiveness of the approved antiviral drugs for mild/moderate infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Hong Kong

George OKOLIThe University of Hong Kong, Hong Kong SAR China
Impact of Antiviral Timing and Vaccination on Viral Shedding in Hospitalized Older Adults with COVID-19 During Omicron Predominance

Yun LINWorld Health Organization Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China, Hong Kong SAR China
Analysis of potential drug combinations against influenza by specifically targeting the viral polymerase

Bahaaeldin ALHAMMADYLeibniz-Institut für Virologie (LIV), Germany
Treatment with pictilisib-loaded lipid nanoparticles reduces influenza A virus infection in vitro and ex vivo

Josefine SCHROEDERJena University Hospital, Germany
Comparative assessment of in vivo antiviral activity of anti-influenza drugs (AD ASTRA)

Podjanee JITTAMALAMahidol University, Thailand
Structural characterization and preclinical development of a heavy chain-only antibody that protects against group 1 and group 2 influenza A viruses

Xavier SAELENSGhent University and VIB, Belgium

SCS

Virus evolution and strain selection SCS13

Auditorium 2 - Breakout

Chairs

Kirsty SHORT

ESWI Associate Member, University of Queensland, Australia

Kairat TABYNOV

Kazakh National Agrarian Research University, Kazakhstan

High-throughput neutralization measurements correlate strongly with evolutionary success of human influenza strains

Caroline KIKAWAFred Hutch/University of Washington, United States
Antigenic mapping of influenza A viruses using deep learning-based prediction of hemagglutination inhibition titers

Bingyi YANGThe University of Hong Kong, Hong Kong SAR China
Site specific predictability of amino acid substitutions of seasonal influenza viruses

Annelies DE ROOIJAmsterdam University Medical Center, Netherlands
Informal settlements and COVID-19: viral phylodynamic, respiratory microbiome, and public health implications.

Mercedes Soledad NABAES JODARRicardo Gutierrez Children Hospital, Argentina
Linking Poultry Supply Chains and Marketing Practices to the Detection of Novel Genotypes Viruses in Bangladeshi Live Bird Markets

To be confirmed

SPI

Transdisciplinary Approaches for Pandemic Preparedness SPI05

Auditorium 3 - Breakout

Chair

Ed HUTCHINSON

ESWI Board Member, University of Glasgow

Leibniz Lab Pandemic Preparedness - a German Initiative for Pandemic Preparedness

Gülsah GABRIELESWI Board Member, Leibniz Institute of Virology, Germany
The Pandemic and Disaster Preparedness Center (PDPC) as a Dutch Initiative for Pandemic Preparedness

Ron FOUCHIERErasmus MC, Netherlands
Prepared Together: Co-Creative Research for Future Pandemics

Sabine MAASENUniversität Hamburg, Germany

15:30 - 16:00

Coffee Break COF06

Exhibition hall

16:00 - 17:30

SCS

Threats from the animal world SCS14 PLE

Auditorium 1 - Plenary Hall

Chairs

Stacey SCHULTZ-CHERRY

St Jude Children's Research Hospital, United States

Kevin CIMINSKI

University Medical Center Freiburg, Germany

Keynote address

Martin BEERFriedrich-Loeffler-Institut, Germany
Genomic insights into the broadening host range of clade 2.3.4.4b H5 avian influenza viruses

Alice FUSAROIstituto Zooprofilattico Sperimentale delle Venezie, Italy
Emergence of a Novel Reassortant Clade 2.3.2.1e Avian Influenza A/H5N1 Virus Associated with Human Cases in Cambodia

Jurre SIEGERSInstitut Pasteur du Cambodge, Cambodia
Increased attachment to and replication of recent avian H5N1 influenza A viruses from clade 2.3.4.4b in human airway epithelial cells

Lisa BAUERErasmus MC, Netherlands
Bovine Myxovirus Resistance Protein 1 mediates antiviral activity against human and avian influenza A viruses

Rubaiyea FARRUKEEUniversity of Melbourne, Australia

17:30 - 19:00

POS

Poster presentations "Microscopes" and refreshments POS02

Poster Halls

Thu 23 Oct 2025

08:15 - 09:15

SAT

Satellite Symposium organised by Pfizer: Unlocking the value of vaccines as a tool to support the management of non-communicable diseases (NCDs) SAT10

Auditorium 1 - Plenary Hall

Chair

Jane BARRATT

Dr Jane Barratt Consulting Inc, Canada

Welcome and introduction

Jane BARRATTDr Jane Barratt Consulting Inc, Canada
The burden of co-circulating vaccine-preventable respiratory diseases

Charles FELDMANUniversity of the Witwatersrand, Australia
The impact of vaccine-preventable respiratory infections on non-communicable diseases

Stefania MAGGIESWI Board Member, National Research Council of Italy, Italy
Advocacy levers to help drive vaccine uptake in eligible populations

Michael MOOREWorld Federation of Public Health Associations, Australia
Audience Q&A and Panel Discussion

Jane BARRATTDr Jane Barratt Consulting Inc, Canada

SAT

Satellite Symposium organised by the ISOLDA consortium: Improved vaccination Strategies for OLDer Adults (ISOLDA) – a Horizon 2020 project SAT12

Auditorium 2 - Breakout

Chair

Ab OSTERHAUS

ESWI Board Member, TiHO, Germany

The magnitude of mRNA COVID-19 vaccine- induced immune responses in older adults inversely correlate with signs of immunosenescence

Guus RIMMELZWAANUniversity of Veterinary Medicine, Hannover, Germany
Reprogrammed T-cell immunity in COVID-19 mRNA-vaccinated young and older adults

David ESCORS-MURUGARRENNavarrabiomed, Spain
Concomitant administration of COVID-19 mRNA and influenza vaccines: a randomized, single blind, clinical trial to assess immunogenicity in adults aged 65 and over

Bart HAAGMANSErasmus Medical Center, Netherlands

SAT

Satellite Symposium organised by ISRV: ISRV 20th Anniversary Lecture: Use of antivirals in pandemics: what have we learnt? SAT04

Auditorium 3 - Breakout

09:30 - 10:30

ECAS

Early Career Scientist Awards and Presentations ECAS03 PLE

Auditorium 1 - Plenary Hall

Chairs

Carolien VAN DE SANDT

ESWI Associate Member, The University of Melbourne at the Doherty Institute, Australia

Colin RUSSELL

ESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands

Award Ceremony

Colin RUSSELLESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands

Carolien VAN DE SANDTESWI Associate Member, The University of Melbourne at the Doherty Institute, Australia
DEI Awards Science Slam

Fiseha Wadilo WADAArmaour Hansen Research Institute, Ethiopia

Shiyamalee ARUNASALAMUniversity of Peradeniya, Sri Lanka

Aida ABBASIReNAp company, Iran

Norosoa Harline RAZANAJATOVOInstitut Pasteur de Madagascar, Madagascar

Sètondji Islamiath KISSIRANational Laboratory of Hemorrhagics and Virals Fevers of Bénin (LFHV), Benin
Another receptor, another tropism: Lessons from bats as influenza A virus reservoirs

Kevin CIMINSKIUniversity Medical Center Freiburg, Germany
Antigenic evolution of influenza B viruses

Marios KOUTSAKOSUniversity of Melbourne, Australia

10:30 - 11:00

Coffee Break COF07

Exhibition hall

11:00 - 12:30

SCS

Virus Structure and replication SCS06

Auditorium 1 - Plenary Hall

Chairs

Ed HUTCHINSON

ESWI Board Member, University of Glasgow

Lisa BAUER

Erasmus MC, Netherlands

Proteomic analysis of the subcellular reorganization during Influenza A infection in human cells

Laura GADEA-SALOMBIOTECMED, Universitat de València, Spain
Influenza NS1-Mediated N(6)-Methyladenosine Modification Controls NS mRNA Splicing

Yingyin LIAOThe University of Hong Kong, Hong Kong SAR China
Reassortment dynamics between clade 2.3.2.1 and 2.3.4.4b A(H5) influenza viruses

Lorin ADAMSThe Francis Crick Institute, UK
Human respirovirus infection driven by heteromultivalent binding of sialoglycotopes

Xander DE HAANUtrecht University, Netherlands
RSV Polymerase L Recruits Rab11a to Facilitate Ribonucleoprotein Transport

Marie-Anne RAMEIX-WELTIInstitut Pasteur CNR Vir (Bat Jacob, France
Transient RNA structure-driven insertions in H5 hemagglutinin required for highly pathogenic avian influenza virus genesis are not dependent on polymerase origin.

To be confirmed

SCS

Virus and host factors in pathogenesis - PART 2 SCS17

Auditorium 2 - Breakout

Chairs

Ron FOUCHIER

Erasmus MC, Netherlands

Mengying LIU

Utrecht University, Netherlands

Respiratory Syncytial Virus G Protein Enhances Viral Dissemination Through TLR2-NFκB-Mediated NLRP3 Priming and Pyroptotic Cell Death

Robert MEINEKEUniversity of Veterinary Medicine Hannover, Germany
Reverse Zoonosis Shapes Transmission and Virulence of Recent H5N1 Clade 2.3.4.4b in Diverse Bird Species

To be confirmed
Autoantibodies against type I IFNs in patients with zoonotic H7N9 infection

Martin SCHWEMMLEUniversity of Freiburg, Germany
Assessing the pathogenicity of contemporary bovine and human clade 2.3.4.4b HPAI H5N1 viruses using human organoid systems representing lung and brain

Emmie DE WITNational Institute of Allergy and Infectious Diseases, United States
Knockdown of Irf9 within vagal sensory ganglia exacerbates disease severity during pulmonary influenza A viral infection

To be confirmed
Genome-wide CRISPR/Cas9 screen identifies host factors potentially modulating influenza A virus polymerase fidelity

To be confirmed

12:30 - 14:00

Farewell Buffet Lunch LUN04

Exhibition hall

14:00 - 15:40

SCS

Late Breakers: novel and outstanding discoveries SCS15 PLE

Auditorium 1 - Plenary Hall

Chairs

Sylvie VAN DER WERF

ESWI Associate Member, Institut Pasteur, France

Carolien VAN DE SANDT

ESWI Associate Member, The University of Melbourne at the Doherty Institute, Australia

mRNA-1010, an mRNA-Based Influenza Vaccine, is Safe and Efficacious in Adults Aged ≥50 Years, Including Individuals at High Risk for Severe Disease

To be confirmed
A real-life study revealed the presence of more than 10% nirsevimab escape mutants in RSV-B breakthrough infections.

Marie-Anne RAMEIX-WELTIInstitut Pasteur CNR Vir (Bat Jacob, France
Prior immunity with seasonal influenza A(H3N2) virus confers varying levels of protection against clade 2.3.4.4b A(H5N1), A(H7N9), or A(H9N2) virus challenge in a ferret model

To be confirmed
Adjuvanted inactivated zoonotic influenza A(H5N8) vaccination induces antibody and T-cell responses to emerging HPAI clade 2.3.4.4b A(H5N1) viruses in healthcare workers

To be confirmed
Translational efficacy of CD388, a novel Drug Fc-Conjugate (DFC), in mouse influenza infection models: application to prevention efficacy in the recently completed Ph2b NAVIGATE clinical study

Voon ONGCidara, United States
Effectiveness of HD-IIV against laboratory-confirmed influenza infection and patient-centered outcomes in the community: a DANFLU-2 sub-study

Filip Soeskov DAVIDOVSKIHerlev and Gentofte Hospital, Denmark
Induction of strong innate immune response in human alveolar epithelium is correlated with pathogenicity of avian influenza viruses

Meaghan FLAGGNIAID, NIH, United States

15:45 - 16:00

PLE

Keynote lecture PLE05

Auditorium 1 - Plenary Hall

Chair

Marco GOEIJENBIER

ESWI Board Member, Spaarne Gasthuis, Netherlands

The FLUNITY-HD study, a prespecified pooled analysis of the DANFLU-2 and GALFLU trials

Tor BIERING-SØRENSENUniversity of Copenhagen, Denmark

16:05 - 16:25

PLE

Closing remarks PLE04

Auditorium 1 - Plenary Hall

Chairs

Colin RUSSELL

ESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands

Ab OSTERHAUS

ESWI Board Member, TiHO, Germany

Stefania MAGGI

ESWI Board Member, National Research Council of Italy, Italy

Marco GOEIJENBIER

ESWI Board Member, Spaarne Gasthuis, Netherlands

Programme chairs

BIO

Ab OSTERHAUS

ESWI Board Member, TiHO, Germany

BIO

Adolfo GARCÍA-SASTRE

Icahn School of Medicine at Mount Sinai, United States

BIO

Anders MADSEN

Haukeland University Hospital, Norway

BIO

Ann MOEN

Task Force for Global Health, United States

BIO

Benjamin COWLING

The University of Hong Kong, Hong Kong SAR China

BIO

Carolien VAN DE SANDT

ESWI Associate Member, The University of Melbourne at the Doherty Institute, Australia

BIO

Catherine WEIL OLIVIER

independent expert, Trustee of CLCI, France

BIO

Colin RUSSELL

ESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands

BIO

Corine GEURTS VAN KESSEL

Erasmus MC, Netherlands

BIO

Debby VAN RIEL

ESWI Associate Member, Erasmus MC, Netherlands

BIO

Ed HUTCHINSON

ESWI Board Member, University of Glasgow

BIO

Florian KRAMMER

ESWI Board Member, Medical University of Vienna, Austria

BIO

George KASSIANOS

ESWI Board Member, G Kassianos

BIO

Guus RIMMELZWAAN

University of Veterinary Medicine, Hannover, Germany

BIO

Jane BARRATT

Dr Jane Barratt Consulting Inc, Canada

BIO

Josefine SCHROEDER

Jena University Hospital, Germany

BIO

Joseph BRESEE

Task Force for Global Health, United States

BIO

Jurre SIEGERS

Institut Pasteur du Cambodge, Cambodia

BIO

Kairat TABYNOV

Kazakh National Agrarian Research University, Kazakhstan

BIO

Kevin CIMINSKI

University Medical Center Freiburg, Germany

BIO

Kevin SELVA

Doherty Institute, University of Melbourne, Australia

BIO

Kirsty SHORT

ESWI Associate Member, University of Queensland, Australia

BIO

Lisa BAUER

Erasmus MC, Netherlands

Litjen (L.J) TAN

Global Influenza Initiative; Immunize.org, United States

BIO

Marco DEL RICCIO

University of Florence, Italy

BIO

Marco GOEIJENBIER

ESWI Board Member, Spaarne Gasthuis, Netherlands

BIO

Marios KOUTSAKOS

University of Melbourne, Australia

Mengying LIU

Utrecht University, Netherlands

BIO

Monika REDLBERGER-FRITZ

Medical University Vienna, Austria

Nico Joel HALWE

Ludwig Boltzmann Gesellschaft, Austria

BIO

Nisreen OKBA

Icahn School of Medicine at Mount Sinai, United States

BIO

Paula TÄHTINEN

ESWI Board Member, Turku University Hospital and University of Turku, Finland

BIO

Ron FOUCHIER

Erasmus MC, Netherlands

BIO

Stacey SCHULTZ-CHERRY

St Jude Children's Research Hospital, United States

BIO

Stefania MAGGI

ESWI Board Member, National Research Council of Italy, Italy

BIO

Sylvie VAN DER WERF

ESWI Associate Member, Institut Pasteur, France

BIO

Ted VAN ESSEN

ESWI Board Member, Netherlands

BIO

Valentino D'ONOFRIO

Ghent University, Belgium

BIO

Weijia XIONG

The University of Hong Kong, Hong Kong SAR China

BIO

Yona TUGG

McMaster University, Canada

Preliminary programme

Sun 19 Oct 2025
Mon 20 Oct 2025
Tue 21 Oct 2025
Wed 22 Oct 2025
Thu 23 Oct 2025

Programme chairs